Datopotamab deruxtecan (Dato-DXd) + Docetaxel
Phase 3Recruiting 3 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non-small Cell Lung Cancer (NSCLC)
Conditions
Non-small Cell Lung Cancer (NSCLC)
Trial Timeline
Oct 31, 2025 → Jan 29, 2029
NCT ID
NCT07291037About Datopotamab deruxtecan (Dato-DXd) + Docetaxel
Datopotamab deruxtecan (Dato-DXd) + Docetaxel is a phase 3 stage product being developed by Daiichi Sankyo for Non-small Cell Lung Cancer (NSCLC). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07291037. Target conditions include Non-small Cell Lung Cancer (NSCLC).
What happened to similar drugs?
20 of 20 similar drugs in Non-small Cell Lung Cancer (NSCLC) were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07291037 | Phase 3 | Recruiting |
Competing Products
20 competing products in Non-small Cell Lung Cancer (NSCLC)